Regeneron Pharmaceuticals Inc. buy Savour
Start price
03.10.20
/
50%
€514.00
Target price
04.11.21
-
Performance (%)
-22.67%
End price
11.03.21
€397.50
Summary
This prediction ended on 11.03.21 with a price of €397.50. The price of Regeneron Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -22.67%. Savour has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 5.324% | 5.324% | 19.781% | 118.463% |
| iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
| iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
| iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
| iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
According to Savour what are the pros and cons of Regeneron Pharmaceuticals Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by Savour for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Buy Regeneron Pharmaceuticals Inc.